GlassScriptPhysician profile
Sunayana Venugopal
NPI 1770187031
$2,280.83
in general payments reported to CMS, 2019-2025
24 companies · $530 in 2025
The $530 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $973 · 2024: $778 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,280.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $300.41 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $299.95 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.74 | 2023-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $221.20 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $217.88 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $210.58 | 2023-2025 | Airsupra, Farxiga |
| Amgen INC. | $139.21 | 2023-2025 | Otezla, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $94.73 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.59 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $60.54 | 2023-2025 | |
| Pfizer INC. | $60.17 | 2024-2025 | |
| Corcept Therapeutics | $51.45 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $38.41 | 2023-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $37.96 | 2023 | Belsomra, Januvia, Steglatro |
| Inspire Medical Systems, INC. | $37.45 | 2024-2025 | Inspire |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $33.73 | 2024 | |
| Phathom Pharmaceuticals, INC. | $31.76 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $28.25 | 2023-2024 | Livalo, Seglentis |
| Axsome Therapeutics, INC. | $25.76 | 2025 | Auvelity |
| Verity Pharmaceuticals INC. | $20.94 | 2025 | Tlando |
| Idorsia Pharmaceuticals US INC | $16.42 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.96 | 2025 | Xifaxan |
| Sanofi Pasteur INC. | $13.81 | 2023 | |
| Janssen Pharmaceuticals, INC | $12.93 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunayana Venugopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.